Cargando…

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation

Posaconazole (PCZ) is frequently used for prophylaxis against invasive fungal infections (IFI) in patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Posaconazole is commercially available as an oral suspension (PCZ-susp) and as a delayed-re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belling, Morgan, Kanate, Abraham S., Shillingburg, Alexandra, Lu, Xiaoxiao, Wen, Sijin, Shah, Nilay, Craig, Michael, Cumpston, Aaron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485328/ https://www.ncbi.nlm.nih.gov/pubmed/28695013 http://dx.doi.org/10.1155/2017/3460892

Ejemplares similares

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf
por: Marques, Gonçalo N., et al.
Publicado: (2021)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis
por: Bentley, Siân, et al.
Publicado: (2021)

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole
por: Soysal, Ahmet
Publicado: (2015)

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient
por: Lykouras, Michail, et al.
Publicado: (2020)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Role of posaconazole in the treatment of oropharyngeal candidiasis
por: Ianas, Voichita, et al.
Publicado: (2010)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
por: Boughton, Charlotte, et al.
Publicado: (2018)

Posaconazole: An Update of Its Clinical Use
por: Leung, Simon, et al.
Publicado: (2015)

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Posaconazole-Induced Apparent Mineralocorticoid Excess
por: Pandit, Amar, et al.
Publicado: (2020)

Posaconazole treatment of refractory coccidioidomycosis in dogs
por: Shubitz, Lisa F., et al.
Publicado: (2021)

Posaconazole: Lack of efficacy: case report
Publicado: (2022)

Posaconazole as rescue therapy in African histoplasmosis
por: Gonçalves, Daniel, et al.
Publicado: (2013)

Formation and Characterisation of Posaconazole Hydrate Form
por: Lykouras, Michail, et al.
Publicado: (2022)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

Role of posaconazole in the management of oropharyngeal and esophageal candidiasis
por: Vazquez, Jose A
Publicado: (2007)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Posaconazole-Induced Hypertension and Hypokalemia: Mechanistic Evaluation
por: Thompson, George R, et al.
Publicado: (2017)

Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs
por: Corrigan, V.K., et al.
Publicado: (2016)

Implications for IV posaconazole dosing in the era of obesity
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Gynecomastia and hypertension in a patient treated with posaconazole
por: Thompson, George R., et al.
Publicado: (2020)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Posaconazole‐induced hypertension in children with cystic fibrosis
por: Marpole, Rachael, et al.
Publicado: (2021)

Erratum for “Posaconazole treatment of refractory coccidioidomycosis in dogs”
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prhnjbsnvk26d5ultjsh2uue2o